Combination of bendamustine-azacitidine against Syk target of breast cancer: an in silico study

References

• Babiker, H. M., Milhem, M., Aisner, J., Edenfield, W., Shepard, D., Savona, M., Iyer, S., Abdelrahim, M., Beach, C. L., Skikne, B., Laille, E., Tsai, K.-T., & Ho, T. (2020). Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemotherapy and Pharmacology, 85(3), 621–626. https://doi.org/10.1007/s00280-020-04037-9
   PubMed Web of Science ®Google Scholar
• Belani, C. P. (2000). Chemotherapy regimens in advanced non–small-cell lung cancer: Implications and future perspectives. Clinical Lung Cancer, 2, S7–S10. https://doi.org/10.3816/CLC.2000.s.007
   PubMedGoogle Scholar
• Blancato, J., Graves, A., Rashidi, B., Moroni, M., Tchobe, L., Ozdemirli, M., Kallakury, B., Makambi, K. H., Marian, C., & Mueller, S. C. (2014). SYK allelic loss and the role of Syk-regulated genes in breast cancer survival. PloS One, 9(2), e87610. https://doi.org/10.1371/journal.pone.0087610
   PubMed Web of Science ®Google Scholar
• Blomgren, P., Chandrasekhar, J., Di Paolo, J. A., Fung, W., Geng, G., Ip, C., Jones, R., Kropf, J. E., Lansdon, E. B., Lee, S., Lo, J. R., Mitchell, S. A., Murray, B., Pohlmeyer, C., Schmitt, A., Suekawa-Pirrone, K., Wise, S., Xiong, J.-M., Xu, J., … Currie, K. S. (2020). Discovery of lanraplenib (GS-9876): A once-daily spleen tyrosine kinase inhibitor for autoimmune diseases. ACS Medicinal Chemistry Letters, 11(4), 506–513. https://doi.org/10.1021/acsmedchemlett.9b00621
   PubMed Web of Science ®Google Scholar
• Butler, C., Sprowls, S., Szalai, G., Arsiwala, T., Saralkar, P., Straight, B., Hatcher, S., Tyree, E., Yost, M., Kohler, W. J., Wolff, B., Putnam, E., Lockman, P., & Liu, T. (2020). Hypomethylating agent azacitidine is effective in treating brain metastasis triple-negative breast cancer through regulation of DNA methylation of keratin 18 gene. Translational Oncology, 13(6), 100775. https://doi.org/10.1016/j.tranon.2020.100775
   PubMed Web of Science ®Google Scholar
• Celik, S., Akyuz, S., & Ozel, A. E. (2022). Vibrational spectroscopic characterization and structural investigations of cepharanthine, a natural alkaloid. Journal of Molecular Structure, 1258, 132693. https://doi.org/10.1016/j.molstruc.2022.132693
   Web of Science ®Google Scholar
• Celik, S., Akyuz, S., & Ozel, A. E. (2023). Molecular modeling, DFT quantum chemical analysis, and molecular docking on edotecarin, an indolocarbazole anticancer agent. Molecular Crystals and Liquid Crystals, 753(1), 27–49. https://doi.org/10.1080/15421406.2022.2084240
   Web of Science ®Google Scholar
• Chinnasamy, S., Selvaraj, G., Kaushik, A. C., Kaliamurthi, S., Chandrabose, S., Singh, S. K., Thirugnanasambandam, R., Gu, K., & Wei, D. Q. (2020). Molecular docking and molecular dynamics simulation studies to identify potent AURKA inhibitors: Assessing the performance of density functional theory, MM-GBSA and mass action kinetics calculations. Journal of Biomolecular Structure & Dynamics, 38(14), 4325–4335. https://doi.org/10.1080/07391102.2019.1674695
   PubMed Web of Science ®Google Scholar
• Choubey, S. K., Mariadasse, R., Rajendran, S., & Jeyaraman, J. (2016). Identification of novel histone deacetylase 1 inhibitors by combined pharmacophore modeling, 3D-QSAR analysis, in silico screening and density functional theory (DFT) approaches. Journal of Molecular Structure, 1125, 391–404. https://doi.org/10.1016/j.molstruc.2016.06.082
   Web of Science ®Google Scholar
• Choubey, S. K., Prabhu, D., Nachiappan, M., Biswal, J., & Jeyakanthan, J. (2017). Molecular modeling, dynamics studies and density functional theory approaches to identify potential inhibitors of SIRT4 protein from homo sapiens: A novel target for the treatment of type 2 diabetes. Journal of Biomolecular Structure & Dynamics, 35(15), 3316–3329. https://doi.org/10.1080/07391102.2016.1254117
   PubMed Web of Science ®Google Scholar
• Cives, M., Ciavarella, S., Rizzo, F. M., De Matteo, M., Dammacco, F., & Silvestris, F. (2013). Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cellular Signalling, 25(5), 1108–1117. https://doi.org/10.1016/j.cellsig.2013.01.020
   PubMed Web of Science ®Google Scholar
• Dominic, J. L., Charlotta, G. L., Paige, A. M., & Ipsita, A. B. (2022). Molecular dynamics, MMGBSA, and docking studies of natural products conjugated to tumor‑targeted peptide for targeting BRAF V600E and MERTK receptors. Molecular Diversity, 27(1), 389–423. https://doi.org/10.1007/s11030-022-10430-8
   PubMed Web of Science ®Google Scholar
• Dubey, P., Gidwani, B., Pandey, R., & Shukla, S. S. (2016). In vitro and in vivo evaluation of PEGylated nanoparticles of bendamustine for treatment of lung cancer. Artificial Cells, Nanomedicine, and Biotechnology, 44(6), 1491–1497. https://doi.org/10.3109/21691401.2015.1052466
   PubMed Web of Science ®Google Scholar
• Eugene, K. G., & Abraham, D. J. (2000). Hydrophobicity: Is LogP(o/w) more than the sum of its parts? European Journal of Medicinal Chemistry, 35(7–8), 651–661. https://doi.org/10.1016/s0223-5234(00)00167-7
   PubMed Web of Science ®Google Scholar
• Fandy, T. (2009). Development of DNA methyltransferase inhibitors for the treatment of neoplastic diseases. Current Medicinal Chemistry, 16(17), 2075–2085. https://doi.org/10.2174/092986709788612738
   PubMed Web of Science ®Google Scholar
• Fandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S. H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., Licht, J., McConnell, M. J., Nasrallah, C., Kim, M. K., Zhang, W., Sun, Y., Murgo, A., Espinoza-Delgado, I., Oteiza, K., … Carraway, H. E. (2009). Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood, 114(13), 2764–2773. https://doi.org/10.1182/blood-2009-02-203547
   PubMed Web of Science ®Google Scholar
• Faryal, R., Ishfaq, M., Hayat, T., Mahjabeen, I., & Kayani, M. A. (2016). Novel SYK gene variations and changes in binding sites of miRs in breast cancer patients. Cancer Biomarkers: Section A of Disease Markers, 16(3), 319–326. https://doi.org/10.3233/CBM-160569
   PubMed Web of Science ®Google Scholar
• Gowrishankar, S., Muthumanickam, S., Kamaladevi, A., Karthika, C., Jothi, R., Boomi, P., Maniazhagu, D., & Pandian, S. K. (2021). Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 – an in silico study. Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research Association, 148, 111966. https://doi.org/10.1016/j.fct.2020.111966
   PubMed Web of Science ®Google Scholar
• Hang, G., Siyue, L., Huanwu, H., Qiufu, G., & Huajun, Z. (2020). Autophagy inhibition potentiates the anticancer effects of a bendamustine derivative NL-101 in acute T lymphocytic leukemia. BioMed Research International, 2020, 1–12. https://doi.org/10.1155/2020/1520651
   PubMed Web of Science ®Google Scholar
• Hansch, C., & Klein, T. E. (1991). Quantitative structure-activity relationships and molecular graphics in evaluation of enzyme-ligand interactions. Methods in Enzymology, 202, 512–543. https://doi.org/10.1016/0076-6879(91)02026-6
   PubMed Web of Science ®Google Scholar
• Hiraoka, N., Kikuchi, J., Yamauchi, T., Koyama, D., Wada, T., Uesawa, M., Akutsu, M., Mori, S., Nakamura, Y., Ueda, T., Kano, Y., & Furukawa, Y. (2014). Purine analog-like properties of bendamustine underlie rapid activation of DNA damage response and synergistic effects with pyrimidine analogues in lymphoid malignancies. PLoS One, 9(3), e90675. https://doi.org/10.1371/journal.pone.0090675
   PubMed Web of Science ®Google Scholar
• Höffken, K., Merkle, K. H., Schönfelder, M., Anger, G., Brandtner, M., Ridwelski, K., & Seeber, S. (1998). Bendamustine as salvage treatment in patients with advanced progressive breast cancer: A phase II study. Journal of Cancer Research and Clinical Oncology, 124(11), 627–632. https://doi.org/10.1007/s004320050225
   PubMed Web of Science ®Google Scholar
• Hu, M., Huang, P., Wang, Y., Su, Y., Zhou, L., Zhu, X., & Yan, D. (2015). Synergistic combination chemotherapy of camptothecin and floxuridine through self-assembly of amphiphilic drug–drug. Bioconjugate Chemistry, 26(12), 2497–2506. https://doi.org/10.1021/acs.bioconjchem.5b00513
   PubMed Web of Science ®Google Scholar
• Huang, P., Wang, D., Su, Y., Huang, W., Zhou, Y., Cui, D., Zhu, X., & Yan, D. (2014). Combination of small molecule conjugate and nanodrug delivery: Amphiphilic drug–drug conjugate for cancer therapy. Journal of the American Chemical Society, 136(33), 11748–11756. https://doi.org/10.1021/ja505212y
   PubMed Web of Science ®Google Scholar
• Kaur, M., & Silakari, O. (2016). Identification of new dual spleen tyrosine kinase (Syk) and phosphoionositide-3-kinase δ (PI3Kδ) inhibitors using ligand and structure-based integrated ideal pharmacophore models. SAR and QSAR in Environmental Research, 27(6), 469–499. https://doi.org/10.1080/1062936X.2016.1209555
   PubMed Web of Science ®Google Scholar
• Kim, E. G., & Kim, K. M. (2015). Strategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeutics. Biomolecules & Therapeutics, 23(6), 493–509. https://doi.org/10.4062/biomolther.2015.116
   PubMed Web of Science ®Google Scholar
• Krisenko, M. O., Cartagena, A., Raman, A., & Geahlen, R. L. (2015). Nanomechanical property maps of breast cancer cells as determined by multiharmonic atomic force microscopy reveal Syk dependent changes in microtubule stability mediated by MAP1B. Biochemistry, 54(1), 60–68. https://doi.org/10.1021/bi500325n
   PubMed Web of Science ®Google Scholar
• Kwon, Y. R., Son, M. J., Kim, H. J., & Kim, Y. J. (2012). Reactivation of silenced WT1 transgene by hypomethylating agents – implications for in vitro modeling of chemoimmunotherapy. Immune Network, 12(2), 58–65. https://doi.org/10.4110/in.2012.12.2.58
   PubMedGoogle Scholar
• Lan, Y., Liang, Q., Sun, Y., Cao, A., Liu, L., Yu, S., Zhou, L., Liu, J., Zhu, R., & Liu, Y. (2020). Codelivered chemotherapeutic doxorubicin via a dual-functional immunostimulatory polymeric conjugate for breast cancer immunochemotherapy. ACS Applied Materials & Interfaces, 12(28), 31904–31921. https://doi.org/10.1021/acsami.0c06120
   PubMed Web of Science ®Google Scholar
• Leoni, L. M., Bailey, B., Reifert, J., Bendall, H. H., Zeller, R. W., Corbeil, J., Elliott, G., & Niemeyer, C. C. (2008). Bendamustine (treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 14(1), 309–317. https://doi.org/10.1158/1078-0432.CCR-07-1061
   PubMed Web of Science ®Google Scholar
• Liu, D., & Mamorska-Dyga, A. (2017). Syk inhibitors in clinical development for hematological malignancies. Journal of Hematology & Oncology, 10(1), 145. https://doi.org/10.1186/s13045-017-0512-1
   PubMedGoogle Scholar
• Martínez, L. (2015). Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis. PloS One, 10(3), e0119264. https://doi.org/10.1371/journal.pone.0119264
   PubMed Web of Science ®Google Scholar
• Maurya, A. K., Mulpuru, V., & Mishra, N. (2020). Discovery of novel coumarin analogs against the α-glucosidase protein target of diabetes mellitus: Pharmacophore-based QSAR, docking, and molecular dynamics simulation studies. ACS Omega, 5(50), 32234–32249. https://doi.org/10.1021/acsomega.0c03871
   PubMed Web of Science ®Google Scholar
• Ming, J., Renping, L., Ying, C., Qisheng, Z., Saijun, F., & Peixun, I. (2014). A combined experimental and computational study of Vam3, a derivative of resveratrol, and Syk interaction. International Journal of Molecular Sciences, 15(9), 17188–17203. https://doi.org/10.3390/ijms150917188
   PubMed Web of Science ®Google Scholar
• Mócsai, A., Ruland, J., & Tybulewicz, V. L. (2010). The SYK tyrosine kinase: A crucial player in diverse biological functions. Nature Reviews. Immunology, 10(6), 387–402. https://doi.org/10.1038/nri2765
   PubMed Web of Science ®Google Scholar
• Muthumanickam, S., Indhumathi, T., Boomi, P., Balajee, R., Jeyakanthan, J., Anand, K., Ravikumar, S., Kumar, P., Sudha, A., & Jiang, Z. (2022). In silico approach of naringin as potent phosphatase and tensin homolog (PTEN) protein agonist against prostate cancer. Journal of Biomolecular Structure and Dynamics, 40(4), 1629–1638. https://doi.org/10.1080/07391102.2020.1830855
   PubMed Web of Science ®Google Scholar
• Mia, I. R., Charlotta, G. L., Saige, M. M., & Ipsita, A. B. (2022). Molecular dynamics simulations, docking and MMGBSA studies of newly designed peptide‑conjugated glucosyloxy stilbene derivatives with tumor cell receptors. Molecular Divers, 26(5), 2717–2743. https://doi.org/10.1007/s11030-021-10354-9
   PubMed Web of Science ®Google Scholar
• Padilla, P. F., Bhagirath, N., Chen, S., Chiao, E., Goldstein, D. M., Hermann, J. C., Hsu, J., Kennedy-Smith, J. J., Kuglstatter, A., Liao, C., Wenjian, L. L. E., Chun, L. K., Lynch, M. S., Menke, J., Niu, L., Owens, T. D., C., O. Y., Railkar, A., Schoenfeld, R. C., Michelle, … X., Zhou, Lucas, M. C. (2013). Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors. Journal of Medicinal Chemistry, 56(4), 1677–1692. https://doi.org/10.1021/jm301720p
   PubMed Web of Science ®Google Scholar
• Pirvulescu, C., von Minckwitz, G., & Loibl, S. (2008). Bendamustine in metastatic breast cancer: An old drug in new design. Breast Care (Basel, Switzerland), 3(5), 333–339. https://doi.org/10.1159/000154105
   PubMed Web of Science ®Google Scholar
• Prajisha, J., Biswal, J., & Jeyakanthan, J. (2022). Discovery of potent Camkk1 kinase inhibitors through e-pharmacophore and molecular screening approaches. Journal of Biomolecular Structure & Dynamics, 40(6), 2740–2756. https://doi.org/10.1080/07391102.2020.1842805
   PubMed Web of Science ®Google Scholar
• Prashant, K., Shadab, M., Nabil, A. A., Khaled, M., & Hosny, A. H. (2021). QbD enabled azacitidine loaded liposomal nanoformulation and its in vitro evaluation. Polymers, 13(2), 250. https://doi.org/10.3390/polym13020250
   PubMed Web of Science ®Google Scholar
• Ramachandran, B., Srinivasadesikan, V., Chou, T. M., Jeyakanthan, J., & Lee, S. L. (2022). Atomistic simulation on flavonoids derivatives as potential inhibitors of bacterial gyrase of Staphylococcus aureus. Journal of Biomolecular Structure & Dynamics, 40(10), 4314–4327. https://doi.org/10.1080/07391102.2020.1856184
   PubMed Web of Science ®Google Scholar
• Ratain, M. J., & Plunkett, W. K. (2003). Principles of pharmacokinetics. Cancer Medicine 6th ed.
   Google Scholar
• Rezkallah, E., Ibrahim, A., Dahy, A., Hakiem, A. A., & Mahfouz, R. (2019). DFT and thermal decomposition studies on gemcitabine. Zeitschrift für Physikalische Chemie, 233(10), 1503–1527. https://doi.org/10.1515/zpch-2018-1304
   Web of Science ®Google Scholar
• Sankar, M., Langeswaran, K., Jeyachandran, S., & Boomi, P. (2021). Screening of inhibitors as potential remedial against Ebolavirus infection: Pharmacophore-based approach. Journal of Biomolecular Structure & Dynamics, 39(2), 395–408. https://doi.org/10.1080/07391102.2020.1715260
   PubMed Web of Science ®Google Scholar
• Sankar, M., Ramachandran, B., Pandi, B., Mutharasappan, N., Ramasamy, V., Prabu, P. G., Shanmugaraj, G., Wang, Y., Muniyandai, B., Rathinasamy, S., Chandrasekaran, B., Bayan, M. F., Jeyakanthan, J., Halliah, G. P., & Ebenezer, S. K. (2021). In silico screening of natural phytocompounds towards identification of potential lead compounds to treat COVID-19. Frontiers in Molecular Biosciences, 8, 637122. https://doi.org/10.3389/fmolb.2021.637122
   PubMed Web of Science ®Google Scholar
• Sarkar, A., & Kellogg, G. E. (2010). Hydrophobicity–shake flasks, protein folding and drug discovery. Current Topics in Medicinal Chemistry, 10(1), 67–83. https://doi.org/10.2174/156802610790232233
   PubMed Web of Science ®Google Scholar
• Spitzer, D., Simon, P. O., Jr., Kashiwagi, H., Xu, J., Zeng, C., Vangveravong, S., Zhou, D., Chang, K., McDunn, J. E., Hornick, J. R., Goedegebuure, P., Hotchkiss, R. S., Mach, R. H., & Hawkins, W. G. (2012). Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signaling. Cancer Research, 72(1), 201–209. https://doi.org/10.1158/0008-5472.CAN-11-1354
   PubMed Web of Science ®Google Scholar
• Singh, P., Islam, S. S., Ahmad, H., & Prabaharan, A. (2018). Spectroscopic investigation (FT-IR, FT-Raman), HOMO-LUMO, NBO, and molecular docking analysis of N-ethyl-N-nitrosourea, a potential anticancer agent. Journal of Molecular Structure, 1154, 39–50. https://doi.org/10.1016/j.molstruc.2017.10.012
   Web of Science ®Google Scholar
• Singh, P., Prabaharan, A., Ahmad, H., & Islam, S. S. (2018). Spectroscopic (ft-ir, ft-Raman and UV-vis) study, homo-lumo, nbo and molecular docking analysis of alkylating agent: Bis-chloroethylnitrosourea. International Journal of Current Research, 10(03), 66290–66307.
   Google Scholar
• Turner, N., Moretti, E., Siclari, O., Migliaccio, I., Santarpia, L., D'Incalci, M., Piccolo, S., Veronesi, A., Zambelli, A., Del Sal, G., & Di Leo, A. (2013). Targeting triple negative breast cancer: Is p53 the answer. Cancer Treatment Reviews, 39(5), 541–550. https://doi.org/10.1016/j.ctrv.2012.12.001
   PubMed Web of Science ®Google Scholar
• Venugopal, P. P., Das, B. K., Soorya, E., & Chakraborty, D. (2020). Effect of hydrophobic and hydrogen bonding interactions on the potency of ß‐alanine analogs of G‐protein coupled glucagon receptor inhibitors. Proteins, 88(2), 327–344. https://doi.org/10.1002/prot.25807
   PubMed Web of Science ®Google Scholar
• Xing, W., Junfang, G., Zhongqi, N., & Xia, W. (2018). Discovery of a natural Syk inhibitor from Chinese medicine through a docking-based virtual screening and biological assay study. Molecules, 23(12), 3114. https://doi.org/10.3390/molecules23123114
   PubMed Web of Science ®Google Scholar
• Zhang, T., Huang, P., Shi, L., Su, Y., Zhou, L., Zhu, X., & Yan, D. (2015). Self-assembled nanoparticles of amphiphilic twin drug from floxuridine and bendamustine for cancer therapy. Molecular Pharmaceutics, 12(7), 2328–2336. https://doi.org/10.1021/acs.molpharmaceut.5b00005
   PubMed Web of Science ®Google Scholar
• Ziemba, A., Hayes, E., Freeman, B. B., Ye, T., & Pizzorno, G. (2011). Development of an oral form of azacytidine: 2′ 3′ 5′ triacetyl-5-azacytidine. Chemotherapy Research and Practice, 2011, 965826. https://doi.org/10.1155/2011/965826
   PubMedGoogle Scholar